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Taiwan as a Clinical Trial
Center of Excellence in the Asia Pacific L ocated in the center of the Asia Pacific region, Taiwan is very active in medical research, having published about 22 585 papers in clinical medicine between 1996 and 2006. Taiwan ranks third in "Country Rankings in Clinical Medicine" in the Asia Pacific, just after Japan and Australia. Taiwan also has good patient resources: with a population of 23 million, it is one of the most densely populated countries in the world. Thus, researchers in Taiwan are always able to finish patient recruitment in their international clinical trials according to tight schedules and timelines. 
Major Pharmaceutical Companies
In some international clinical trials sponsored by major pharmaceutical companies, the quality of clinical trials performed in Taiwan is ranked among the best by worldwide institutions. Taiwan has demonstrated clinical research excellence in its national vaccination program against the hepatitis B virus (HBV) as well as in the prevention of HBV liver disease and hepatocellular carcinoma. Ribavirin combined with interferon treatment -for which its use in successfully treating chronic hepatitis C was first reported by the National Taiwan University Hospital in 1996 -has been one of the biggest breakthroughs in the treatment of patients with chronic hepatitis C virus infection in the last 15 years. Taiwan is also active in clinical genomic research; for instance, an article on the discovery of a five-gene signature that predicts the prognosis and treatment outcome of lung cancer patients, also by the National Taiwan University Hospital, Taiwan ranks third in "Country Rankings in Clinical Medicine" in the Asia Pacific, just after Japan and Australia. 
